Details of the Drug Reposition

General Information of This Drug (ID: DMRHGI9)

Drug Name
Cisplatin   DMRHGI9
Synonyms
Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
18 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Urinary bladder neoplasm DIS7HACE N.A. Approved [1]
Testicular germ cell tumor DIS5RN24 N.A. Approved [1]
Sarcomatoid mesothelioma DISCCHZN N.A. Approved [1]
Primitive neuroectodermal tumor DISFHXHA N.A. Approved [1]
Primary peritoneal carcinoma DISKYEDV N.A. Approved [1]
Posterior urethra cancer DIS3DNQW N.A. Approved [1]
Gastric intestinal type adenocarcinoma DISEO8Y0 N.A. Approved [1]
Extragonadal germ cell tumor DISE6LY9 N.A. Approved [1]
Central nervous system neoplasm DISFC18W N.A. Approved [1]
Anterior urethra cancer DISAKHZJ N.A. Approved [1]
Carcinoma DISH9F1N 2A00-2F9Z Approved [1]
Plasma cell myeloma DIS0DFZ0 2A83.1 Approved [1]
Epithelial ovarian cancer DIS56MH2 2B5D Approved [1]
Gastroesophageal junction adenocarcinoma DISCVPML 2B71 Approved [1]
Small-cell lung cancer DISK3LZD 2C25.Y Approved [1]
Adenocarcinoma DIS3IHTY 2D40 Approved [1]
Esophageal squamous cell carcinoma DIS5N2GV 2E60.1 Approved [1]
Epithelioid mesothelioma DIS17SNY 2F10 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 Indications(s)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Osteosarcoma DISLQ7E2 2B51 Phase 2 [2]
------------------------------------------------------------------------------------
4 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Medulloblastoma DISZD2ZL 2A00.10 Withdrawn [3]
Ovarian cancer DISZJHAP 2C73 Withdrawn [4]
Nausea and vomiting DISZBU97 MD90 Withdrawn [5]
Acute radiation syndrome DISZA94A NF00 Withdrawn [6]
------------------------------------------------------------------------------------
5 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Neoplasm of esophagus DISOLKAQ N.A. Discontinued in Phase 2 [7]
Esophageal adenocarcinoma DISODWFP N.A. Discontinued in Phase 2 [8]
Ureter cancer DISOUKYP N.A. Discontinued in Phase 2 [9]
Squamous cell carcinoma DISQVIFL 2B60-2D01 Discontinued in Phase 2 [10]
Xerostomia DISS4GU8 DA02.1 Discontinued in Phase 2 [11]
------------------------------------------------------------------------------------
1 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Diffuse gastric adenocarcinoma DISTAPUS N.A. Discontinued in Phase 1 [12]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Gastric cancer DISXGOUK 2B72 Investigative [1]
------------------------------------------------------------------------------------

References

1 Cisplatin FDA Label
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01007773) Safety of Dexmedetomidine in Severe Traumatic Brain Injury
4 Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy
5 Treatment of Iron Overload Requiring Chelation Therapy
6 Bevacizumab With or Without Surgery for Adult Glioblastomas
7 Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
8 A Folinic Acid Intervention for Autism Spectrum Disorders
9 ClinicalTrials.gov (NCT00038376) Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
10 ClinicalTrials.gov (NCT02029417) Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
11 Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
12 ClinicalTrials.gov (NCT01204450) Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma